Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17583744 | 0.77 | KMT2A (0.66) | CYP19A1TSHRKMT2ASLC6A4SLC6A3 | |
| SCHEMBL982063 | 0.76 | ALDH1A1 (0.44) | TSHRKMT2ASLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8267772 | 0.76 | SLC6A4 (0.40) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL13698283 | 0.73 | CYP19A1 (0.54) | CYP19A1TSHRKMT2ASLC6A4SLC6A3 | |
| SCHEMBL983389 | 0.72 | CYP19A1 (0.52) | CYP19A1TSHRKMT2ASLC6A4SLC6A3 | |
| SCHEMBL13698259 | 0.72 | CYP19A1 (0.59) | CYP19A1TSHRKMT2ASLC6A4SLC6A3 | |
| SCHEMBL13698263 | 0.70 | CYP19A1 (0.50) | CYP19A1TSHRKMT2ABRD4 | |
| SCHEMBL13698264 | 0.70 | CYP19A1 (0.56) | CYP19A1TSHRKMT2ASLC6A4SLC6A3 | |
| SCHEMBL13698277 | 0.70 | CYP19A1 (0.56) | CYP19A1TSHRKMT2ASLC6A4SLC6A3 | |
| Phensuximide SCHEMBL35334 | 0.69 | KMT2A (1.00) | CYP19A1TSHRKMT2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257545-B1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | HOFFMAN-LA ROCHE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021556-A1 | PYRROLIDINYL DERIVATIVES AND USES THEREOF | SLC6A3, MAOB, TPH2 | CYP19A1 472/4885TSHR 1389/4885KMT2A 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.